Clinical experience of somatrem: UK preliminary report

Acta Paediatr Scand Suppl. 1986;325:25-8. doi: 10.1111/j.1651-2227.1986.tb10359.x.


A total of 63 patients with hGH deficiency were recruited, of whom 59 are evaluable. Somatrem (Somatonorm), 4 IU three times/week, was given either subcutaneously or intramuscularly. Height velocity increased from a mean of 4.7 +/- 2.1 cm/year before therapy to 8.2 +/- 2.6 cm/year in the 15 patients who have been followed for 1 year. In patients with isolated hGH deficiency height velocity increased similarly to the whole group, but in those with multiple pituitary hormone deficiencies the pretreatment and on-treatment growth velocities were lower. Of four children who had previously received spinal irradiation, three experienced only a small increase in height velocity on Somatonorm treatment; the fourth showed a considerable increase in height velocity. Anti-hGH antibodies were present in about 80% of the children tested after 12 months of treatment, but the titres and binding capacities were low. Anti-ECP antibodies were also detected, but again the titres were low, and 39% of the children tested had anti-ECP antibodies before treatment commenced.

Publication types

  • Clinical Trial

MeSH terms

  • Antibody Formation
  • Child
  • Clinical Trials as Topic
  • Growth / drug effects
  • Growth / radiation effects
  • Growth Hormone / adverse effects
  • Growth Hormone / analogs & derivatives*
  • Growth Hormone / deficiency
  • Growth Hormone / immunology
  • Growth Hormone / therapeutic use
  • Human Growth Hormone
  • Humans
  • Spine / radiation effects
  • United Kingdom


  • Human Growth Hormone
  • Growth Hormone